Table 2.

Chemotherapy regimens at PCNSL presentation

TreatmentPatients, n
MTX-based27
 FAB/LMB 96a 9
 Bonn protocolb 2
 CALGB-50202c 1
 POG-9906d 1
 COG-ANHL0131/Ae 1
 IA-MTX/IV Cy + BBBDf 2
 MTX (225 mg) + vincristine (2.5 mg)1
 MTX/vincristine + other regimensg 3
 HD-MTX (5 g/m2) + HD-Ara-C (3 g/m2)3
 HD-MTX (3.5–5 g/m2) + other chemotherapy drugsh 4
Non-MTX based2
 CCNU1
 Vincristine/prednisone/doxorubicin1
  • aFAB (French-American-British) LMB 96 = COPADM × 2: cyclophosphamide, vincristine, prednisone, cytarabine, doxorubicin, intravenous MTX (5–8 g/m2); CYVE × 2: cytarabine (3 g/m2), etoposide.

  • bMTX (3 g/m2), vincristine, ifosfamide, dexamethasone, intra-omaya chemotherapy, cytarabine (3g/m2), and vindesine.

  • c MTX (3.5 g/m2), rituximab, temozolomide, cytarabine, and etoposide.

  • dPOG (Pediatric Oncology Group) 9906-Acute Lymphoblastic Leukemia Protocol: vincristine, prednisone, doxorubicin, l-asparaginase; cyclophosphamide, cytarabine, 6-mercaptopurine plus IT MTX; intravenous MTX (5 g/m2), vincristine; oral 6-mercaptopurine plus oral MTX in maintenance. Patient also received 1,200 cGy WBRT.

  • eCOG (Children's Oncology Group) ANHL0131-Regimen A-Anaplastic T-Large Cell Lymphoma Protocol: vincristine, prednisone, l-asparaginase, doxorubicin plus IT MTX; oral MTX plus 6-mercaptopurine/prednisone in maintenance.

  • fIA-MTX: intra-arterial MTX (1.5–2.5 g/m2) × 2 days, IV Cy: intravenous cyclophosphamide (15 mg/kg/d) × 2 days, BBBD for a total of 12 months.

  • gOther regimens included cyclophosphamide, doxorubicin, ifosfamide, cytarabine, and etoposide.

  • hOther chemotherapy drugs included thiotepa (35 mg/m2)/cytarabine (n = 1), vincristine/procarbazine (n = 1), vincristine/cyclophosphamide/dexamethasone (n = 1), rituximab/ifosfamide/carboplatin/etoposide (n = 1).